scispace - formally typeset
Open AccessJournal Article

The legal and clinical implications of crushing tablet medication.

Anthony James
- 01 Jan 2004 - 
- Vol. 100, Iss: 50, pp 28-29
Reads0
Chats0
TLDR
There may be times when tablets will need to be crushed in order to deliver essential drug therapy; this should only be done as a last resort.
Citations
More filters
Patent

Abuse-proofed dosage forms

TL;DR: In this article, a form of administration which is secured against misuse and which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances.
Patent

Pharmaceutical dosage form

TL;DR: In this article, a pharmaceutical dosage form with controlled release of a pharmacologically active compound (A) contained therein, the dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a break strength B2 of less than 500 n in direction E2.
Journal Article

Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.

TL;DR: It may be concluded that when considering the safety and efficacy of liquid dosage forms prepared extemporaneously, it is thus important to consider not only the stability of the drug substance but the entire formulation.
Patent

Process for the production of an abuse-proofed dosage form

TL;DR: In this paper, a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
Patent

Crush resistant delayed-release dosage forms

TL;DR: In this paper, the authors defined a dosage form comprising a physiologically effective amount of a physically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic or natural wax (D), where the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance from the dosage forms is at least partially delayed.